Drug Patents owned by Horizon

1. List of Duexis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8449910 HORIZON Stable compositions of famotidine and ibuprofen
Jul, 2026

(3 years from now)

US8309127 HORIZON Stable compositions of famotidine and ibuprofen
Jul, 2026

(3 years from now)

US8318202 HORIZON Stable compositions of famotidine and ibuprofen
Jul, 2026

(3 years from now)

US8501228 HORIZON Stable compositions of famotidine and ibuprofen
Jul, 2026

(3 years from now)

US8067451 HORIZON Methods and medicaments for administration of ibuprofen
Jul, 2026

(3 years from now)

Drugs and Companies using FAMOTIDINE; IBUPROFEN ingredient

Market Authorisation Date: 23 April, 2011

Treatment: Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for those indications

Dosage: TABLET;ORAL

How can I launch a generic of DUEXIS before it's patent expiration?
More Information on Dosage

2. List of Pennsaid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168304 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9132110 HORIZON Treatment of pain with topical diclofenac
Oct, 2027

(4 years from now)

US9168305 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9066913 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9339551 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9220784 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9339552 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9539335 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US8563613 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US8871809 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US9101591 HORIZON Diclofenac topical formulation
Oct, 2027

(4 years from now)

US8252838 HORIZON Diclofenac topical formulation
Apr, 2028

(5 years from now)

US9415029 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(6 years from now)

US9370501 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(6 years from now)

US8618164 HORIZON Treatment of pain with topical diclofenac compounds
Jul, 2029

(6 years from now)

US8741956 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(6 years from now)

US9375412 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(6 years from now)

US8217078 HORIZON Treatment of pain with topical diclofenac
Jul, 2029

(6 years from now)

US8546450 HORIZON Treatment of pain with topical diclofenac compounds
Aug, 2030

(7 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Market Authorisation Date: 16 January, 2014

Treatment: Use of topical diclofenac for treating pain; Use of topical diclofenac sodium for treating pain; Use of topical diclofenac on a joint for treating osteoarthritis; Use of topical diclofenac on the knee and a second topical prescription medication on the same knee; Combination use of topical diclofenac on the knee and administration of an oral nsaid.; Use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant

Dosage: SOLUTION;TOPICAL

How can I launch a generic of PENNSAID before it's patent expiration?
More Information on Dosage

3. List of Procysbi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9925157 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

US9925158 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

US9925156 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192590 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

US9198882 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(3 years from now)

US9192590

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(4 years from now)

US9925156

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(4 years from now)

US9925157

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(4 years from now)

US9198882

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(4 years from now)

US9925158

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(4 years from now)

US8026284 HORIZON Enterically coated cystamine, cysteamine and derivatives thereof
Sep, 2027

(4 years from now)

US8026284

(Pediatric)

HORIZON Enterically coated cystamine, cysteamine and derivatives thereof
Mar, 2028

(5 years from now)

US9173851 HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Jun, 2034

(11 years from now)

US9233077 HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Jun, 2034

(11 years from now)

US9173851

(Pediatric)

HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Dec, 2034

(11 years from now)

US9233077

(Pediatric)

HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Dec, 2034

(11 years from now)

US10905662 HORIZON Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(13 years from now)

US10548859 HORIZON Methods for storing Cysteamine formulations and related methods of treatment
Aug, 2036

(13 years from now)

US10328037 HORIZON Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(13 years from now)

US10143665 HORIZON Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(13 years from now)

US10905662

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(14 years from now)

US10328037

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(14 years from now)

US10143665

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(14 years from now)

US10548859

(Pediatric)

HORIZON Methods for storing Cysteamine formulations and related methods of treatment
Feb, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 22, 2024
Pediatric Exclusivity (PED) Feb 14, 2023

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 30 April, 2013

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of PROCYSBI before it's patent expiration?
More Information on Dosage

4. List of Rayos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309124 HORIZON Delayed release tablet with defined core geometry
Apr, 2024

(1 year, 2 months from now)

US8394407 HORIZON Delayed release tablet with defined core geometry
Apr, 2024

(1 year, 2 months from now)

US9186332 HORIZON Delayed release tablet with defined core geometry
Apr, 2024

(1 year, 2 months from now)

US9040085 HORIZON Delayed release tablet with defined core geometry
Apr, 2024

(1 year, 2 months from now)

US9504699 HORIZON Delayed-release glucocorticoid treatment of rheumatoid disease
Aug, 2027

(4 years from now)

US8168218 HORIZON Delayed release tablet with defined core geometry
Jan, 2028

(4 years from now)

Drugs and Companies using PREDNISONE ingredient

Market Authorisation Date: 26 July, 2012

Treatment: Treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet; Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet; Treatment of rheumatologic, allergic, pulmonary, gastrointestinal, dermatologic diseases or conditions by the use of a delayed release 5mg prednisone tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of RAYOS before it's patent expiration?
More Information on Dosage

5. List of Vimovo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9345695 HORIZON Pharmaceutical compositions for the coordinated delivery of NSAIDs
May, 2022

(8 months ago)

US8858996 HORIZON Pharmaceutical compositions for the coordinated delivery of NSAIDS
May, 2022

(8 months ago)

US8852636 HORIZON Pharmaceutical compositions for the coordinated delivery of NSAIDs
May, 2022

(8 months ago)

US9161920 HORIZON Pharmaceutical compositions for the coordinated delivery of NSAIDs
May, 2022

(8 months ago)

US9198888 HORIZON Pharmaceutical compositions for the coordinated delivery of NSAIDs
May, 2022

(8 months ago)

US9707181 HORIZON Pharmaceutical compositions for the coordinated delivery of NSAIDs
May, 2022

(8 months ago)

US9393208 HORIZON Method for delivering a pharmaceutical composition to patient in need thereof
Sep, 2029

(6 years from now)

US9220698 HORIZON Method for delivering a pharmaceutical composition to patient in need thereof
Mar, 2031

(8 years from now)

US8945621 HORIZON Method for treating a patient at risk for developing an NSAID-associated ulcer
Oct, 2031

(8 years from now)

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM; NAPROXEN ingredient

Market Authorisation Date: 30 April, 2010

Treatment: Relief of signs and symptoms of arthritis and risk-reduction of nsaid-associated gastric ulcer; Risk-reduction of nsaid gastric ulcer in patients requiring chronic nsaid treatment; Risk-reduction of nsaid-associated gastric ulcer in patients requiring nsaid treatment; Risk-reduction of nsaid-associated gastric ulcers in patients also taking low dose aspirin

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of VIMOVO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic